ImmunoGenesis develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms. Because these “cold” tumors (the majority of cancers) are resistant to immunotherapy, our team strives to create sophisticated therapies that target key mechanisms of immune resistance. We look at cold tumors through a new lens, re-envisioning treatment with a deliberate drug development strategy based in cold tumor pathology.